Tianeptine: why lawmakers fear a new kind of opioid
The drug is sold over the counter. And is highly addictive.
The U.S. is suffering from an opioid problem, and now a dangerous drug is being sold in the country's gas stations and convenience stores. This especially accessible drug, tianeptine, is marketed as a dietary supplement but, in a manner similar to opioids, is causing addiction and overdose deaths across the country. Lawmakers want the government to take stronger measures against the distribution of tianeptine.
What is tianeptine?
Tianeptine, also called "gas station heroin," is an unregulated antidepressant "promoted by retailers as a mood booster and focus aid," The New York Times explained. The drug is not approved for use in the U.S. and "although other countries have approved tianeptine to treat depression and anxiety, some have restricted how tianeptine is prescribed or dispensed, or revised the drug label to warn of possible addiction," according to the U.S. Food and Drug Administration (FDA). Many have used the drug as a way to get high, as a dietary supplement or to self-medicate for depression and anxiety. Tianeptine has been sold under many brand names, including Stablon, Tatinol and Coaxil, and as an ingredient in products marketed as dietary supplements such as Tianaa, Neptune's Fix, Zaza and Pegasusin. The drug is available across the U.S. in gas stations and convenience stores and can also be purchased online.
Researchers have found that using tianeptine has similar effects to using opioids. "We have people who are able to get a substance that's not well regulated, that has abuse potential and that, in high doses, can cause similar effects to opioids, leading to really harmful outcomes," Kaitlyn Brown, clinical managing director of America's Poison Centers, told the Times. There are also no quality and purity standards that tianeptine manufacturers abide by. Sometimes naloxone, a drug created to reverse opioid overdoses, can help with tianeptine overdoses, but it doesn't show consistent effectiveness. There were 391 cases of tianeptine exposure reported to America's Poison Centers in 2023, compared to only four in 2013.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Because of the lack of regulation, "consumers are usually taking a gamble when they buy tianeptine products because they can't know for sure how much of the drug they're getting," according to Popular Science. This can lead to unwanted overdoses and other side effects associated with opioid use and include "lethargy, elevated blood pressure and heart rate, agitation, abdominal pain, tremors and hallucinations." The source added, "Those who regularly misuse the pills may exhibit withdrawal symptoms such as stomachaches and anxiety if they try to quit."
What actions are being taken?
While the FDA has warned about tianeptine, "more action on tianeptine use is needed to ensure the health and well-being of the American people," according to a letter written by five House representatives to the FDA commissioner. Currently, Alabama, Florida, Georgia, Indiana, Kentucky, Michigan, Mississippi, Ohio and Tennessee have banned the drug.
"There are now at least a dozen different products that are foreign drugs being openly marketed as dietary supplements right under the FDA's eyes, without them being able to stop the sales," Dr. Pieter Cohen, an associate professor at Harvard Medical School, told The New York Times. The FDA advised on its website that "consumers should avoid all products containing tianeptine, including those claiming to treat an ailment or disorder." However, the agency hasn't taken any further action to regulate the drug. A representative for the FDA wrote to Popular Science, stating that "the FDA generally cannot confirm or deny the existence of any possible product application," and "a drug sponsor would need to submit an application to the agency for review," in order for it to be approved or denied for medical use. In the meantime, individual states alone are responsible for placing regulations on the drug.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
The decline of the contraceptive pill
In the Spotlight Fears of the pill's side effects, stoked by social media, behind switch to fertility trackers – or no contraception at all
By Harriet Marsden, The Week UK Published
-
The UK's first legal drug consumption room
The Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
By The Week UK Published
-
Walking pneumonia cases are picking up pace
The explainer Another respiratory illness to be wary of
By Devika Rao, The Week US Published
-
Drugmakers paid pharmacy benefit managers to avoid restricting opioid prescriptions
Under the radar The middlemen and gatekeepers of insurance coverage have been pocketing money in exchange for working with Big Pharma
By Theara Coleman, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
The future of fluoridated water is up for debate
The Explainer The oral benefits are watery
By Devika Rao, The Week US Published
-
Will the murder of a health insurance CEO cause an industry reckoning?
Today's Big Question UnitedHealthcare CEO Brian Thompson was shot and killed in what police believe was a targeted attack
By Justin Klawans, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published